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Abstract
Hepatic resection offers a chance of a cure in selected patients with colorectal liver metastases (CLM). To
achieve adequate patient selection and curative surgery, (i) precise assessment of the extent of disease,
(ii) sensitive criteria for chemotherapy effect, (iii) adequate decision making in surgical indication and (iv)
an optimal surgical approach for pre-treated tumours are required. For assessment of the extent of the
disease, contrast-enhanced computed tomography (CT) and/or magnetic resonance imaging (MRI) with
gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is recommended depend-
ing on the local expertise and availability. Positron emission tomography (PET) and PET/CT may offer
additive information in detecting extrahepatic disease. The RECIST criteria are a reasonable method to
evaluate the effect of chemotherapy. However, they are imperfect in predicting a pathological response in
the era of modern systemic therapy with biological agents. The assessment of radiographical morpho-
logical changes is a better surrogate of the pathological response and survival especially in the patients
treated with bevacizumab. Resectability of CLM is dependent on both anatomic and oncological factors.
To decrease the surgical risk, a sufficient volume of liver remnant with adequate blood perfusion and
biliary drainage is required according to the degree of histopathological injury of the underlying liver. Portal
vein embolization is sometimes required to decrease the surgical risk in a patient with small future liver
remnant volume. As a complete radiological response does not signify a complete pathological response,
liver resection should include all the site of a tumour detected prior to systemic treatment.
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Pre-therapeutic imaging evaluation of
colorectal liver metastases
Adequate pretreatment imaging is critical for patients with sus-
pected colorectal cancer (CRC) liver metastases for diagnosis,
staging, pre-surgical and treatment planning, and post-treatment
evaluation. The goals of pre-operative imaging in patients with
CRC liver metastases are to: (i) define the number and segmental/
lobar distribution, (ii) determine surgical resectability and (iii)
identify any extra-hepatic disease.1
Imaging techniques and results in CRC
liver metastases
Options available for hepatic imaging include ultrasound (US),
computed tomography (CT), magnetic resonance imaging (MRI)
and fluorodeoxyglucose-positron emission tomography (FDG-
PET). The modality of choice will be dictated by local availability
and expertise, the limitations and purpose of the study and prior
imaging results.
US and contrast-enhanced US
Transabdominal US plays a limited role in the diagnosis of CRC
liver metastases, given its limited sensitivity of 50–75%2 and its
operator-dependent nature.However, it may be the initial imaging
choice in centres with expertise. The addition of intravenous (i.v.)
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contrast improves sensitivity by about 20%, results similar to
those seen with MDCT (multi-detector CT).2–4 The use of per-
flubutane ultrasound microbubbles (Sonazoid; Amersham
Health, Princeton, NJ, USA) improves detection and characteri-
zation of focal liver lesions.5 Liver lesions are detected with higher
sensitivity using Sonazoid-enhanced US compared with CECT
(contrast-enhanced CT), especially for small tumours.6,7 However,
US contrast agents are not Food and Drug Administration
approved in the United States.
The best reference standard for the detection of liver metastases
is intra-operative US (IOUS) combined with surgical exploration,
typically performed at the time of hepatic surgery.8,9 IOUS often
alters the pre-operative surgical plan.10 In a comparison between
IOUS and helical CT on 250 patients undergoing surgical resec-
tion, IOUS detected additional tumours in 27% of patients.11 Even
improvements in cross-sectional imaging did not alter the benefi-
cial role of IOUS, which altered surgical management in 20% of
patients in two different time periods to account for improve-
ments in CT scanning.12 However, advances in MDCT and MRI
ultimately may reduce the utility of IOUS.13,14 More recent results
advocate the use of contrast-enhanced IOUS (CE-IOUS) based on
a study of 60 patients with CRC.15 CE-IOUS had greater sensitivity
compared with CT/MR and IOUS (96.1% vs. 76.7% and 81.5%,
respectively). Similar to transabdominal ultrasound, a limitation
of IOUS is its operator dependence.
Multidetector row CT (MDCT)
MDCT is routinely used for the detection of CRC liver and lung
metastases.16 MDCT offers high temporal and spatial resolution, is
widely available and relatively inexpensive. Contrast enhancement
with a bolus-tracking technique is required for optimization of
arterial and portal venous phase imaging and the detection of
lesions. The arterial phase of enhancement is typically obtained
20–30 s after the injection of contrast, whereas the portal venous
phase is obtained at approximately 60 s. Generally, CRC metas-
tases are hypovascular, more evident during portal venous phase
imaging,17 appearing hypodense compared with normal liver
parenchyma, often demonstrating rim enhancement that subse-
quently washes out on later phases.13 Arterial phase imaging using
a high contrast injection rate is useful for surgical planning as it
delineates vascular anatomy and the relationship of intrahepatic
lesions to these structures.
Liver metastases have a variable appearance on unenhanced CT,
with the majority being hypointense. Calcifications may occur
with mucinous adenocarcinoma.18 A limitation of CT is the
patient exposure to ionizing radiation and the potential for reac-
tions to iodinated contrast. A second common limitation is the
inability to adequately characterize sub-centimetre lesions, which
are too small to accurately differentiate as metastatic or benign,
even in patients with known primary malignancies.19,20
MRI
Recent technological advances in hardware and software, together
with the development of a variety of MR contrast agents have
madeMRI the most accurate imaging technique for detection and
characterization of liver masses, including metastases.21–23 MRI
does not use ionizing radiation, offers higher contrast resolution
and the possibility of performing multiparametric imaging,
combining T1, T2, and diffusion-weighted imaging (DWI) with
dynamic multiphasic contrast imaging. State of the art MRI now
routinely offers thin 3D T1-weighted dynamic acquisitions.24 In
addition, 3T MRI offers higher spatial resolution compared with
1.5T MRI, owing to the improved signal-to-noise ratio. CRC liver
metastases are generally hypointense on T1W pre-contrast,
slightly T2 hyperintense, with restricted diffusion (bright on high
b-value diffusion with low apparent diffusion coefficient, except in
necrotic metastases25). After gadolinium contrast injection, CRC
metastases generally display a hypovascular enhancement pattern,
with internal enhancement on portal venous or late venous phase
images.26 Perilesional enhancement in the form of circular or
wedge-shaped enhancement may also be seen.27 Compared
with CT, MRI has the potential advantage of increased lesion
conspicuity given the number of different imaging sequences
employed.25 DWI also improves liver lesion conspicuity compared
with T2W sequences.28,29
Several i.v. contrast agents with differing performance charac-
teristics are available to improve detection and characterization of
liver lesions.30 Extracellular gadolinium chelates such as gadopen-
tetate dimeglumine (Gd-DTPA, Magnevist; Bayer Healthcare
Pharmaceuticals, Berkeley, CA, USA) are used routinely in
abdominal MRI. Hepatobiliary agents such as gadobenate dimeg-
lumine (Gd-BOPTA; Multihance, Bracco Diagnostics, Princeton,
NJ, USA) or gadoxetate disodium (Gd-EOB-DTPA, Eovist or Pri-
movist; Bayer Healthcare Pharmaceuticals) can improve charac-
terization of small liver lesions as they are taken up by normal liver
parenchyma, but excluded from metastatic lesions.31,32 Shimada
et al.33 assessed detection of small metastatic lesions (2 cm),
using a 3T system, showing an area under the curve (AUC) of
0.958–0.966 for Gd-EOB-DTPA and 0.881–0.906 for DWI (for
two observers). Lowenthal et al.34 demonstrated superiority of
Gd-EOB-DTPA enhanced MRI for the detection of CRC metas-
tases (detection rate 94.4% and 100% for 2 observers) compared
with DWI (78.3% and 97.5%). The delayed hepatocyte phase
images after administration of Gd-EOB-DTPA have the disadvan-
tage of missing small hepatic lesions near small vascular struc-
tures; these are better detected with DWI.35,36 Recently, Koh et al.
showed the combination of DWI and Gd-EOB-DTPA-enhanced
T1 weighted imaging significantly improved the detection of CRC
liver metastases, over each technique alone.36 The primary limita-
tions of MRI are costs, contra-indications, and access to special-
ized techniques and the expertise to interpret them.
PET and PET/CT
F18-FDG-PET imaging detects metabolically active tumour cells.
Optimal PET imaging is performed with concurrent CT, provid-
ing a metabolic map of glucose uptake throughout the entire
body. PET is routinely used in the evaluation of patients with
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malignancies, demonstrating high sensitivity and specificity for
detection of liver metastases, with the advantage of detection of
extrahepatic metastases, which can have profound implications
for patient management.37 PET and PET/CT are superior to CT or
MRI for detection of extrahepatic metastases, local recurrence, or
diagnosis of indeterminate hepatic lesions.38–42 The use of i.v. con-
trast during the CT portion of a PET/CT examination improves
the detection of CRC liver metastases.43 However, PET is less effec-
tive for the diagnosis of small pulmonary nodules or the detection
of intrahepatic recurrence especially in patients who have under-
gone chemotherapy.44 Other limitations of PET/CT imaging
include limited availability, cost and the uncertainty surrounding
its utility and the timing of its use during treatment planning for
CRC metastases.
Comparison between imaging modalities
Each imaging modality has specific advantages and disadvantages,
related to cost, speed of acquisition, the use of ionizing radiation,
the risk of contrast reaction, and local availability and expertise.
Sensitivity and specificity reported for different imaging modali-
ties depend on a number of factors. These include the number of
patients, their tumour burden (high tumour burden patients will
have many subcentimetre lesions, lowering overall sensitivity), the
reference standard used (preferably histological examination of
resected specimens), the prevalence of incidental benign lesions
(which will affect the specificity), the contrast agent used for MRI
(hepatobiliary agents, extracellular Gd chelates), previous chemo-
therapy and the presence of fatty liver.
Available evidence supports the use of MRI for the detection of
CRC liver metastases based on two recent meta-analyses. Floriani
et al.45 compiled 25 articles and showed that sensitivity and spe-
cificity on a per-patient basis for US, CT,MRI and FDG-PET were
63.0% and 97.6%, 74.8% and 95.6%, 81.1% and 97.2, and 93.8%
and 98.7%, respectively. On a per-lesion basis, sensitivity was
86.3%, 82.6%, 86.3% and 86.0%, respectively. MRI showed a
better sensitivity than CT in per-patient and per-lesion analysis. In
per-lesion analysis, the difference was higher when liver-specific
contrast agents were administered.Niekel et al.46 compiled 39 arti-
cles (3391 patients) and showed the following estimates of sensi-
tivity per-lesion: CT 74.4%, MRI 80.3% and FDG PET 81.4%.
Per-patient sensitivities were CT 83.6%, MRI 88.2% and FDG
PET 94.1%. The per-patient sensitivity of CT was lower than that
of FDG PET (P = 0.025). Specificity estimates were comparable.
For lesions smaller than 10 mm, the sensitivity estimates for MRI
were higher than those for CT.No differences were seen for lesions
measuring at least 10 mm. In this meta-analysis, the use of liver-
specific contrast material and MDCT scanners did not provide
improved results. Data about FDG PET/CT were too limited for
comparisons with other modalities. It was concluded that MRI
was the preferred first-line modality for evaluating untreated CRC
liver metastases.46 Seo et al.47 compared Gd-EOB-DTPA enhanced
MRI (using 3T) with CE-PET/CT, and demonstrated a AUC of
0.94 vs. 0.81 for Gd-EOB-MRI vs. CE-PET/CT for all lesion sizes
(P < 0.001), 0.92 vs. 0.60 for lesions1 cm (P < 0.001) and 0.88 vs.
0.96 for lesions >1 cm (P = 0.098), respectively. It was concluded
that Gd-EOB-enhanced MRI using a 3T system is more accurate
than CE-PET/CT, especially for the detection of small (1.0 cm)
lesions.
Finally, MRI is more sensitive for the detection of small CRC
metastases (1 cm) compared with CT in the presence of chemo-
therapy associated steatosis.48
Consensus statement
1 The choice of imaging technique for pre-treatment assessment
of colorectal liver metastases depends on local expertise and
availability.
2 However, when the technical and interpretive expertise is
available:
a MRI combining Gd-EOB-DTPA delayed images and
diffusion-weighted imaging has the best performance char-
acteristics for detecting and characterizing liver lesions, par-
ticularly those < 1 cm in size. However, increased sensitivity
may be associated with reduced specificity.
b In patients with steatosis or changes secondary to pre-
operative chemotherapy,MRI is more sensitive for the detec-
tion of metastatic lesions and is the preferred imaging
technique for these patients.
3 PET and PET/CT are useful for detecting extra-hepatic metas-
tases and local recurrence. However, it is less effective for the
diagnosis of small pulmonary nodules or the detection of small
liver metastases.
Imaging evaluation of response
Imaging is the cornerstone of response evaluation in oncology.
Established methods of evaluation rely on changes in tumour size
as defined by the WHO and RECIST criteria.49–51 The advent of
targeted and locoregional therapies, however, are increasingly
drawing attention to the shortcomings of this method while at the
same time, advances in molecular imaging and image processing
are opening up new opportunities for response evaluation.52
Inconsistent agreement between the objective response and
patient outcome underscores the need to establish better criteria.53
Several sophisticated new methods exploring the response to
treatment, such as perfusion CT and MRI, diffusion-weighted
imaging and texture evaluation, are in the developmental
stages.52,54–58 In clinical practice, a tumour response in hepatic
CRCmetastasis can be evaluated from three different perspectives:
• a change in tumour size
• morphological changes unrelated to size
• functional imaging, using F18-FDG PET.
Change in tumour size
A change in tumour size is quantified and categorized into one of
four groups used to judge the effect of the drug. The WHO crite-
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ria, the first attempt at standardization, uses bidimensional meas-
urements. In 2000, RECIST criteria were introduced to simplify
data collection and increase standardization.49 The RECIST crite-
ria were revised in 2009 to clarify the evaluation of nodal disease,
refine the definition of Progressive disease (PD) and further sim-
plify data collection. The RECIST criteria use unidimentional
measurement and are based on the sum of the maximal transverse
diameters of up to five target lesions measured before and after
treatment. The percentage difference between the two measure-
ments is used to categorize treatment response. Broadly, partial
response (PR) is defined by a decrease of at least 30% of the
pretreatment sum. PD is defined by an increase of at least 20% and
at least 5 mm in the sum, or a new lesion.51 A complete response
(CR) is defined by the disappearance of all lesions and stable
disease (SD) by a lack of change.51 It is extremely important to
note that although radiological CR may reflect pathological CR, it
is not always synonymous with pathological CR. Consequently, all
metastatic sites identified on pre-chemotherapy imaging need to
be resected.59 This highlights the critical value of high-quality
pre-chemotherapy scans.
A change in tumour size is a strong indicator of a response, but
recent studies have questioned the clinical value of the categorical
definitions of RECIST, and the choice of threshold values that
were developed in an era when precise measurements were not
feasible. The need for a 30% decrease in tumour size derives from
historical data collected at a time when a precise measurement was
impossible. Today, the available imaging techniques allow better
estimation. Two recent studies show that an early decrease in size
of 10% correlates better with outcome than the established 30%
decrease by RECIST.60,61 These results indicate the cut-off value
and optimal time of evaluation need reappraisal.
Non-size-based morphological parameters
Increasingly, studies recognize morphological features as valid
indicators of a response, particularly with targeted therapy. Fea-
tures such as modification of the tumour texture, enhancement
and margins are reflections of a response regardless of a change in
tumour size.51,62 This correlation was first observed with gastroin-
testinal stromal tumours (GIST), leading to establishment of the
Choi criteria.62 Similar changes occur in hepatic CRC metastases
treated with bevacizumab-containing chemotherapy.63 Hepatic
CRC metastases typically are heterogeneous with poorly defined
margins. Tumours with an optimal response to therapy become
homogeneous with sharp margins lacking enhancement. They
acquire a pseudocystic appearance. Comparison of the subjec-
tively judged pretreatment and post-treatment morphological
characteristics allows classification of patients into optimal,
partial or non-responders. The morphological radiographical
response correlates very well with the pathological response, is a
better indicator of a minor pathological response (with more than
50% of viable tumour) than RECIST, and correlates with overall
survival.63 It is important to note these criteria have been
described with high-quality CT,63 but are not yet validated with
MRI. These criteria need to be validated in independent studies.
Functional imaging with F18-FDG PET
Many authors advocate using F18-FDG PET for response evalua-
tion in hepatic CRC metastases.64 Although a metabolic response
reflects tumour volume, the data are insufficient to support the
routine use of F18-FDG PET for response assessment in meta-
static CRC.65 Importantly, the sensitivity of PET decreases after
systemic chemotherapy44 and PET, like CT, is not an accurate
indicator of a complete pathological response.66 The most recent
publication on the subject indicates that PET can identify
patients that will not benefit from treatment after only one cycle
of chemotherapy.67
Consensus statement
1 The RECIST criteria are routinely used criteria; however, they
are limited for assessing a response to systemic and locoregional
therapy in hepatic CRC. Newer data demonstrate the need to
reassess the response criteria.
2 Morphological assessment is a better surrogate of a pathologi-
cal response and survival than the RECIST criteria in patients
receiving bevacizumab. However, this needs to be validated in
larger independent studies.
3 The role of PET in evaluating a treatment response in meta-
static CRC is undefined. Therefore, its routine use in this cir-
cumstance is not indicated.
Definition of resectability
After confirmation of medical fitness for general anaesthesia and
major abdominal surgery, the eligibility for resection in patients
with CRC metastases is determined by two domains: oncological
and technical. From an oncological perspective, evaluation for
extrahepatic disease and the response to pre-operative systemic
therapy are the main considerations. From a technical perspective,
resection is the preferred treatment option if all viable tumours
can be removed with negative margins, while leaving an adequate
functional liver remnant.
Oncological resectability
From an oncological perspective, in the era of effective systemic
therapy, the goal of complete resection of all viable disease in
patients with CRC liver metastases is critical as they are the most
likely to benefit from this approach. This applies to extirpation of
both intra- and extrahepatic disease.
Extrahepatic disease
All patients with CRC liver metastases require adequate pre-
operative staging for the biochemical and radiological presence,
location, multiplicity, volume and resectability of extrahepatic
disease. Excluding the case of synchronous disease at the primary
tumour site, the most common sites of extrahepatic disease
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include recurrent colorectal involvement, intra-abdominal lymph
node involvement and lung metastases.68 Several previous studies
report long-term post-hepatectomy survival in highly selected
patients with clinically apparent extrahepatic disease.68–74 These
studies have defined clinical variables associated with poor out-
comes including a positive resection margin,68,71,72 extrahepatic
disease site,72–74 number of metastases68,72,73 and an unanticipated
intra-operative diagnosis.71,72 In particular, regarding extrahepatic
disease sites, patients with isolated lung metastases or periportal
adenopathy have the best 5-year survivals (30–40%).72 Those with
limited volume peritoneal disease have intermediate 5-year sur-
vivals (15–30%), whereas patients with aortocaval adenopathy or
multiple sites of disease rarely benefit from liver resection (5-year
survivals <15%).75 Furthermore, whether these variables are
present or absent, posthepatectomy recurrence in patients with
extrahepatic disease is nearly universal, ranging from 84% to
95%.71–73,75
These data suggest that patients harbouring limited extrahe-
patic disease amenable to surgical resection (e.g. isolated portal
lymphadenopathy) or with reasonable expectations for long-term
control with adjuvant therapies (e.g. small volume lung disease)
and who have responded to pre-operative systemic therapy could
be considered for hepatic resection.When the extrahepatic disease
burden is not resectable or controllable, a hepatic metastasectomy
is contraindicated.
Response to systemic therapy
When patients are treated with pre-operative systemic therapy
prior to a hepatic resection, the patient and surgeon benefits by
observing the biological behaviour of the tumour. Although
uncommon with modern systemic therapy regimens, patients
occasionally (5–15%) will progress during administration of sys-
temic therapy, demonstrating growth of known lesions and/or
development of new lesions.76 Considering the potency of current
therapy, disease progression represents a marker for aggressive
tumour biology. Allen et al. in 200377 and Adam et al. in 200478
recognized the association between progression during pre-
operative systemic therapy and poor post-hepatectomy survival.
The previous study by Adam et al. indicated that in patients with
> 3 liver metastases who progressed on chemotherapy the 5-year
survival after liver resection was only 8%.78 A more recent study
challenges this concept,79 finding no relationship between the pre-
operative therapy response and survival. However, only 44% of
patients in this study received modern therapy regimens com-
pared with 85% in the Adam study.
Progression in the form of development of new lesions, regard-
less of location, is the strongest predictor of poor post-
hepatectomy outcomes.78 When patients progress in the form of
new lesions during pre-operative chemotherapy, additional con-
siderations include confirmation that the patient received a
modern chemotherapy regimen, performance of tumoural
genetic testing (i.e. K-ras and B-raf) and administration of
second-line systemic therapy.80 In contrast, the prognostic impact
of progression in the form of pre-existing intrahepatic lesion
growth during pre-operative chemotherapy is unclear, suggesting
that patients with this pattern of progression and anatomically
resectable lesions may remain candidates for a hepatectomy.
Technical resectability
Assessment of technical resectability requires a multifaceted
analysis of liver anatomy, histology and function, best analyzed in
a multidisciplinary setting with input from hepatobiliary sur-
geons, radiologists, hepatologists and pathologists. The previously
proposed definition of technical resectability mandating ‘a margin
negative removal of all viable tumours leaving a minimum of two
contiguous segments of hepatic parenchyma with adequate vas-
cular inflow and outflow and adequate biliary drainage’ has served
the surgical community well.1 More recently, the ability to accu-
rately predict the future liver remnant volume and function
has optimized the selection of patients with resectable CRC
metastases.
Assessment of adequate postoperative (remnant)
liver volume
Liver volumetry permits quantification of the anticipated future
liver remnant (FLR) volume.81,82 This allows patient stratification
for the risk of liver failure after a major hepatectomy.Additionally,
FLR assessment can guide selection of candidates whomay benefit
from portal vein embolization (PVE).83–87 Studies confirm FLR
hypertrophy after PVE, allowing a major hepatectomy in patients
who were previously technically unresectable because the FLR was
too small. This approach also lowers the risk of post-operative
liver insufficiency for patients with borderline FLR volumes.85,87–89
These data support the concept that patients with a normal liver,
in general, will tolerate a reduction in liver volume to 20%. Those
with chemotherapy-induced liver injury require a FLR volume of
approximately 30% and those with cirrhosis require at least a 40%
residual volume.81,90,91
Assessment of remnant liver function
The FLR volume after a major hepatectomy does not account for
all the factors contributing to early post-operative liver insuffi-
ciency and mortality. In addition to the volume, function of the
FLR has evolved as an important factor for consideration. Thus,
technical resectability takes into account liver anatomy, FLR
volume and function. Eastern countries use ICG excretion as a
critical assay to assess liver function,84,92 and consequently, resecta-
bility. ICG excretion is not widely available in the West, thus
surgeons have reliedmore on laboratory assessments of liver func-
tion, such as solitary values (e.g. serum bilirubin) or aggregate
scores (e.g. model for end-stage liver disease93). For patients with
abnormal liver laboratories and/or imaging, a liver biopsy may
confirm the presence of histological abnormalities. This informa-
tion is combined with clinical expertise to decide whether the
patient’s liver function is sufficient to support a hepatectomy.
With increased utilization of pre-operative systemic chemo-
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therapy,94 and the epidemics of obesity95 and viral hepatitis,96 it
has become increasingly hazardous to perform a major hepatec-
tomy in the absence of an objective measure of FLR function.
One of the few accurate tests available for the assessment of the
functional and regenerative capacity of the FLR is PVE.81–84 The
FLR’s ability to hypertrophy in response to PVE is a highly reliable
indicator of the function of the remnant liver. Therefore, hyper-
trophy should be considered another criteria for resectability in
patients with marginal FLR volumes.85,86 Furthermore, recent data
indicates a high risk of post-operative liver failure for patients
with marginal FLR volumes when the FLR does not hypertrophy
after PVE by at least 5 percentage points. Although the liver con-
tinues to hypertrophy over time after PVE, patients without
adequate hypertrophy within 10 weeks of a technically successful
PVE should be approached with extreme caution.85
Resectional strategies
The suitability of a surgical strategy for the treatment of CRC
metastases is evaluated by its safety and oncological efficacy.With
limited liver tumour burden, including small volume and ana-
tomically favourably positioned bilateral metastases, a one-stage
strategy involving one or more simultaneous partial to lobar
hepatic resections is safe and effective.97–102When extensive bilobar
metastases are present, several surgical strategies are available. The
most frequently utilized is a two-stage strategy with initial resec-
tion of tumours within the future liver remnant contralateral to
planned PVE, followed by percutaneous PVE and a subsequent
ipsilateral second-stage resection. The percutaneous technique of
PVE is more effective at inducing liver hypertrophy than simple
portal ligation.103,104 For patients who are candidates for this
approach and complete the second stage, long-term survivals are
equivalent to patients with more limited disease treated with a
conventional single-stage strategy.103
Several recent publications describe novel approaches to treat
patients with extensive bilobar CRC metastases.105–108 While inno-
vative, current experience with these techniques is limited and the
data available regarding the safety and oncological profile are
insufficient to advocate any of these as valid resectional strategies.
Margin status
The acceptable margin width necessary when resecting CRC liver
metastases has been debated for decades. Prior to effective sys-
temic therapy, studies identified a survival advantage when a
negative margin width of 1 cm was achieved and a consensus
developed that this margin width was not only optimal, but
defined resectability.109–111 Recent studies that include patients
treated with pre-operative systemic therapy, consistently have
found that the resection margin width, as long as no tumour cells
are microscopically present at the margin, does not impact long-
term survival.112–116 Two recent detailed analyses provide the
genetic and pathological bases for this argument.117,118
Several authors hypothesize that surgical transection tech-
niques and effective chemotherapy minimize the impact of a sub-
centimeter margin on long-term outcomes. One group suggests
the prognostic distinction between R0 and R1 (microscopically
positive margin) is diminishing in the current era of systemic
chemotherapy.119 Unfortunately, more definitive conclusions
regarding optimal and acceptable margins of resection are con-
founded by differences in study patient populations, includ-
ing the per cent of patients receiving modern pre-operative
chemotherapy.
Combined, these studies support a consensus that resectability
of CRC liver metastases be based on a minimal goal of achieving
a margin-negative resection. Therefore, patients with hepatic
metastases, regardless of the anatomic distribution or relationship
to critical structures, should be considered resectable if the margin
is expected to be a grossly and microscopically negative margin in
a patient with a sufficiently sized FLR.
Conclusions
Published experience supports determination of resectability
in patients with CRC liver metastases based on an adequate
imaging evaluation and consideration of both oncological and
technical aspects. From an oncological perspective, patients with
limited and favourably located extrahepatic disease that is
durably controllable with a second treatment modality and
patients with minimal progression of existing disease during
administration of pre-operative systemic therapy may still
benefit from a hepatic resection and should be considered
resectable.
From a technical perspective, the ability to remove all viable
metastasis with negative microscopic margins, leaving a
minimum of two contiguous segments of hepatic parenchyma
with adequate vascular inflow and outflow, adequate biliary drain-
age and adequate functional regenerative capacity defines resecta-
bility. Any surgical approach with a proven record of safety and
long-term oncological benefit that adheres to these principles is
valid as a resectional strategy.
Consensus statement
Oncological criteria of resectability
1 Prior to considering resection of CRC hepatic metastases, pre-
treatment radiological staging is required to assess for the pres-
ence and extent of intra- and extrahepatic disease.
2 Patients harbouring limited extrahepatic disease amenable to
surgical resection or with reasonable expectations for long-
term control with adjuvant therapies may be considered for a
hepatic resection.
3 Patients with significant progression of metastatic disease
(growth in more than three existing liver metastases and/or the
development of multiple new lesions) during treatment with
optimal pre-operative chemotherapy should have a surgical
resection deferred until achieving disease control with second-
line systemic or regional therapies.
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Technical criteria of resectability
1 Resectability includes the expectation that a margin-negative
resection (i.e. R0) can be achieved.
2 The technical feasibility of a hepatic resection should be based
on four criteria related to the liver remnant after resection:
a the anticipated ability to preserve two contiguous segments
b the anticipated ability to preserve adequate vascular inflow,
outflow and biliary drainage
c the anticipated ability to preserve adequate FLR volume
(20% in normal liver and 30% in pretreated liver with
chemotherapy)
d the demonstrated ability of the FLR to adequately function
based on the appropriate regenerative response after PVE in
patients with a marginal FLR volume and/or underlying liver
disease.
Management of the disappearing metastasis
A subset of patients with CRC liver metastasis will be treated with
pre-operative chemotherapy. Pre-operative chemotherapy can be
used to treat patients with unresectable liver metastasis or in the
neoadjuvant setting before surgery for resectable liver metasta-
sis.76,77,120,121 New chemotherapeutic and targeted agents have
higher response rates than previous systemic agents.59,122 The
pathological response to pre-operative chemotherapy is strongly
predictive of prognosis after a resection,123; however, the fate of
patients with a complete radiological response is unclear.59 The
entity ‘disappearing’ metastases describes the complete radio-
logical response after effective chemotherapy leading to several
institutional reports describing their experiences with this
situation.59,122,124–127 Disappearing metastases become a problem
when they are outside of the field of planned surgery. As such they
should be defined as ‘missing’ metastases. It is best to avoid the
problem of ‘missing’ liver metastasis by early involvement of the
liver surgeon, preferably before the initiation of chemotherapy. In
addition, limiting the duration of chemotherapy to a fixed, short
course (e.g. in the neoadjuvant setting) or a response adequate to
allow surgical resection (e.g. ‘conversion’ chemotherapy) is desir-
able. Placing fiducials or coils to mark small metastases at risk of
becoming ‘missing’ before chemotherapy assists intra-operative
localization of DLM.128
The incidence of disappearing liver metastasis (DLM) ranges
from 5% to 38%.59,122,124–127 A complete radiological response
depends, however, on the quality and completeness of pre-
operative imaging.129 Until recently, contrast-enhancedmulti-slice
CT has been the primary imaging modality for CRC liver metas-
tasis with sensitivities ranging from 60% to 90%.15,130–132 However,
pre-operative chemotherapy can cause steatosis or steatohepatitis,
limiting the accuracy, interpretation, and consequently, the utility
of CT for evaluating CRC liver metastasis.133–135 Recent reports
indicate MRI is superior to a CT scan for pre-operative charac-
terization of CRC liver metastasis and the response to therapy
after preoperative chemotherapy.132 Auer et al. note that the inabil-
ity to observe DLM on MRI is strongly associated (OR, 4.7; P =
0.005) with a true complete response at histology.122 In this study,
of the seven DLM detected at the site of its disappearance, six were
detected by MRI. In a meta-analysis evaluating varying pre-
operative imaging modalities, Bipat et al. note that MRI is more
accurate than CT for detecting lesions after pre-operative chemo-
therapy.130 These data support usingMRI to evaluate patients with
DLM as the best imaging technique to assess for residual disease
and delineate those patients with a ‘true’ radiological complete
response.
Among patients with DLM an extensive search for the lesions,
including full mobilization of the liver, palpation and intra-
operative ultrasound, is essential at the time of surgery.136
Contrast-enhanced intra-operative ultrasonography is more sen-
sitive for detecting DLM, finding an additional 10%–15% DLM
vs. palpation and unenhanced ultrasonography.136 The ability to
detect DLM at the time of surgery ranges from 27% to
45%.59,122,124,127 Benoist et al. report observing macroscopic disease
among 24% of patients in spite of a pre-operative CT scan (in this
study, metastases were evaluated only on CT-scan) showing a
complete response.59 More recently, van Vledder et al. report
intra-operative detection of DLM in 45% of patients undergoing
surgery.127 The variability in detecting DLM at the time of surgery
is undoubtedly multifactorial, but the most likely contributor is
the quality of the pre-operative imaging. Specifically, the ability to
detect the site of DLM is more common among patients without
pre-operative MR imaging, suggesting these lesions are not ‘true’
complete responders, but rather are simply lesions undetected in
the absence of MR imaging.122,124,125
The concordance between a complete clinical/radiological
response and a complete pathological response is variable, ranging
from 20% to 100%.59,124–127 Benoist et al. reported viable tumour
cells in 80% of pathologically examined specimens containing a
DLM after short duration pre-operative chemotherapy and no
targeted biological therapy.59 van Vledder et al. reported a com-
plete pathological response in 35% of DLM that were detected and
resected. Others report a higher response, observing complete
pathological responses in 58% of DLM, which were incorporated
in the resection specimen, but not detected at the time of sur-
gery.127 Elias et al.124 reported a pathological complete response of
45%,whereas Auer et al.122 noted a complete response of 65%. The
variability in complete pathological response rates probably is
related to type and duration of chemotherapy.129 For groups
employing hepatic arterial infusion therapy, the incidence of a
complete pathological response is much higher.122,124,125 Specifi-
cally, Elias et al. reported a complete response rate of 86% among
patients receiving hepatic arterial infusion therapy prior to
surgery vs. 22% for those receiving systemic chemotherapy
alone.124,125 Collectively these data demonstrate that a complete
radiological response is not equivalent to a complete pathological
response.
In addition to a pathological response, DLM may result in a
durable clinical response. In reviewing the literature, investigators
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defined a durable clinical response as DLMwithout recurrence on
follow-up imaging over a period of time (usually 1 year).59,122,124,127
Previous reports indicate a higher incidence of recurrence for
DLM left in situ when other resected DLM exhibit an incomplete
pathological response.129 Benoist et al. showed that a complete
pathological response of 20% correlates with a similarly low
durable clinical response of 25%.59 van Vledder et al. reported 17
patients with unidentified, untreated DLM, who develop local
recurrence at the initial site of disease in 10 (59%), with a median
time to intra-hepatic recurrence of 11 months.127 Again, similar to
data on a pathological response, a durable clinical response is
more likely after hepatic arterial therapy. Tanaka et al. reported
nearly a 100% durable response after treatment with hepatic arte-
rial infusion therapy.126 Elias et al. used post-operative hepatic
arterial infusion therapy achieving a durable response in 70% of
patients.124 Auer et al. reported that most lesions, when they recur,
do so 10 to 20 months after cessation of chemotherapy.122
Not surprisingly, most studies report a higher rate of intrahe-
patic recurrence among patients with untreated DLM compared
with those having complete resection of the DLM.127 In several
series, DLM recur in more than one-half of patients when the
DLM are not resected.59,127A post-operative adjuvant hepatic
arterial infusion results in a lower incidence of intrahepatic
recurrence.122,124–126 Overall 5-year survival for patients with DLM
ranges from 40% to 80%.59,122,124–127 Several reports find no statis-
tically significant difference in overall survival among patients
with some untreated DLM vs. those in whom all original DLM
sites were excised.127,129
Because a complete pathological or durable clinical response
for DLM occurs in only 20% to 40% of patients treated with
systemic chemotherapy, surgical resection of CRC liver metastasis
should include all original sites of disease. This recommendation
is particularly pertinent when a major hepatectomy is not
required and a limited resection has the potential to leave DLM in
situ. In the situation of a mixed response to therapy, when some
metastases disappear while other areas have residual macroscopic
disease, the clinical approach is more controversial. While the
recommendation is resection of all original sites of disease
including the DLM, this is not always feasible. Resection of
residual macroscopic disease while leaving DLM untreated may
be reasonable in select patients, therefore, this approach is not
considered an absolute contraindication to surgery.129 Selective
resection of residual macroscopic disease with or without some of
the sites of DLM, while leaving other DLM sites untreated is
appropriate only in a multidisciplinary setting. Prior to surgery,
a chemotherapy break is valuable to allow a better evaluation as
to whether, or which, DLM truly represent a durable clinical
response off chemotherapy. The goal of such an approach is to
extirpate all macroscopic or residual sites of disease while assum-
ing that the untreated, non-recurrent DLM sites will remain qui-
escent. One should consider resuming systemic chemotherapy or
hepatic arterial infusion therapy in the adjuvant setting with this
approach.129
Consensus statement
1 A complete radiological response does not signify a complete
pathological response as residual microscopic disease can be
expected in up to 90% of patients with resected DLM treated
with pre-operative systemic chemotherapy.
2 From a surgical perspective, not all ‘disappearing’ liver metas-
tases and only those ‘missing’ (i.e. outside of planned resection
field) are relevant.
3 Multidisciplinary assessment with appropriate imaging prior to
chemotherapy would minimize the occurrence of ‘missing’
metastases.
4 In patients with metastases at risk of disappearing and missing
at surgery, placement of a fiduciary marker by interventional
radiology should be considered.
5 Because a complete pathological or durable clinical response
for DLM occurs in only 20% to 40% of patients treated with
systemic chemotherapy, surgical resection of CRC liver metas-
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